文献速递免疫规划卫生政策与健康促进

下一代流感疫苗在英格兰和威尔士的潜在成本效果:一项模型分析

The potential cost-effectiveness of next generation influenza vaccines in England and Wales: A modelling analysis.
PubMed 文献 · Vaccine · 2023-08-24

研究采用数学模型评估下一代流感疫苗在英格兰和威尔士的流行病学影响与成本效果,基于已有拟合模型数据,评价从提高效力持续时间与广度的改良疫苗到符合世界卫生组织(WHO)优先产品特性(PPC)的通用疫苗等多种新疫苗,与当前季节性疫苗接种规划比较,计算增量成本效果比与增量净货币效益。结果显示下一代流感疫苗可能使流感感染减少21%至77%,取决于疫苗特性;在2019年接种覆盖率水平下,使用任何此类疫苗在支付意愿阈值2万英镑时均具高度成本效果。

要点

  • 下一代流感疫苗可能使流感感染减少21%至77%,取决于疫苗特性。
  • 在2019年接种覆盖率水平下,使用任何下一代疫苗在支付意愿阈值2万英镑时均具高度成本效果。
  • 最佳下一代疫苗的阈值价格为每剂230英镑(95%CrI 192至269英镑,2019年英镑)。

核心结论

  • 下一代流感疫苗可能对流感流行产生影响,并可能具有成本效果特征,为全面疫苗价值评估提供证据,支持下一代流感疫苗开发与推广的投资论证。

研究设计与样本

  • 研究采用数学模型方法,使用已有拟合模型的数据,评估下一代流感疫苗在英格兰和威尔士的流行病学影响与成本效果,所有分析在R中完成。

主要发现

  • 下一代流感疫苗可能使流感感染减少21%至77%,取决于疫苗特性。
  • 经济模型显示,在2019年接种覆盖率水平下使用任何下一代疫苗,在支付意愿阈值2万英镑时均具高度成本效果。
  • 最佳下一代疫苗的阈值价格为每剂230英镑(95%CrI 192至269英镑,2019年英镑)。
  • 即使最低限度改良的流感疫苗也可定价为每剂18英镑(95%CrI 16至21英镑)并仍保持成本效果。

关键数值与推荐

  • 下一代流感疫苗可能使流感感染减少21%至77%,取决于疫苗特性。
  • 在2019年接种覆盖率水平下使用任何下一代疫苗,在支付意愿阈值2万英镑时均具高度成本效果。
  • 最佳下一代疫苗的阈值价格为每剂230英镑(95%CrI 192至269英镑,2019年英镑)。
  • 最低限度改良的流感疫苗可定价为每剂18英镑(95%CrI 16至21英镑)并仍保持成本效果。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Next generation influenza vaccines are in development and have the potential for widespread health and economic benefits. Determining the potential health and economic impact for these vaccines is needed to drive investment in bringing these vaccines to the market, and to inform which groups public health policies on influenza vaccination should target. We used a mathematical modelling approach to estimate the epidemiological impact and cost-effectiveness of next generation influenza vaccines in England and Wales. We used data from an existing fitted model, and evaluated new vaccines with different characteristics ranging from improved vaccines with increased efficacy duration and breadth of protection, to universal vaccines, defined in line with the World Health Organisation (WHO) Preferred Product Characteristics (PPC). We calculated the cost effectiveness of new vaccines in comparison to the current seasonal vaccination programme. We calculated and compared the Incremental Cost-Effectiveness Ratio and Incremental Net Monetary Benefit for each new vaccine type. All analysis was conducted in R. We show that next generation influenza vaccines may result in a 21% to 77% reduction in influenza infections, dependent on vaccine characteristics. Our economic modelling shows that using any of these next generation vaccines at 2019 coverage levels would be highly cost-effective at a willingness to pay threshold of £20,000 for a range of vaccine prices. The vaccine threshold price for the best next generation vaccines in £-2019 is £230 (95%CrI £192 - £269) per dose, but even minimally-improved influenza vaccines could be priced at £18 (95%CrI £16 - £21) per dose and still remain cost-effective. This evaluation demonstrates the promise of next generation influenza vaccines for impact on influenza epidemics, and likely cost-effectiveness profiles. We have provided evidence towards a full value of vaccines assessment which bolsters the investment case for development and roll-out of next-generation influenza vaccines.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Waterlow NR, Procter SR, van Leeuwen E, et al. The potential cost-effectiveness of next generation influenza vaccines in England and Wales: A modelling analysis. Vaccine. 2023. PMID: 37633749. doi:10.1016/j.vaccine.2023.08.031

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。